Two seemingly unrelated Native American children have one painful thing in common: juvenile Pagets disease (JPD), an extremely rare, bone metabolism disorder. Now, researchers at Washington University School of Medicine in St. Louis and Shriners Hospitals for Children, St. Louis, have discovered that the two patients also share an unusual genetic defect. The research team found that both patients are completely missing the gene for a recently discovered protein called osteoprotegerin, known to protect bone. The study is the first to identify a genetic cause for JPD and is published in the July 18 issue of the New England Journal of Medicine.
"By identifying this genetic defect in two people, our results not only provide insight into the cause of JPD, but also shed light on the control of bone metabolism in general," says lead investigator Michael P. Whyte, M.D., professor of medicine, genetics, and pediatrics at the School of Medicine and director of the Center for Metabolic Bone Disease and Molecular Research at Shriners Hospitals for Children. "Understanding how the skeleton forms and breaks down is key to developing ways to diagnose and treat bone disorders in children and adults, including adult Pagets disease and osteoporosis."
JPD, also known as hereditary hyperphosphatasia or hyperostosis corticalis deformans juvenilis, has only been reported in about 40 people worldwide. It is a painful skeletal disease characterized by abnormally fast formation and breakdown of bone throughout the body, resulting in debilitating fractures and deformities beginning soon after birth. These features are similar to the much more common adult disease called Pagets disease of bone, the second most prevalent metabolic bone disorder after osteoporosis. However, JPD appears to affect all bones in the body, whereas Pagets disease of bone involves only a select few.
The Washington University and Shriners team examined DNA samples from two Native Americans. The first was referred to St. Louis from New Mexico in 1996 for confirmation of diagnosis and treatment at one year of age. The team later learned that a second JPD patient, described in the medical literature in 1979, also was living in New Mexico. The second patient contacted the investigators and voluntarily sent her blood samples for genetic study.
The team first evaluated the gene for RANK in these two patients. In a previous collaborative study, they had identified a RANK defect as the cause of three other rare but somewhat similar genetic bone disorders also characterized by accelerated bone metabolism. The two Navajo patients, however, had normal RANK genes.
The researchers next tested the gene that makes osteoprotegerin, a protein discovered only a few years ago. Osteoprotegerin is related functionally to RANK and recent studies have found that mice lacking the protein have a condition where bone formation and breakdown is rapid, seemingly similar to osteoporosis.
The results were surprising. Neither patient had any trace of the gene for osteoprotegerin.
"At first we thought there must be something wrong with our DNA studies," says Steven Mumm, Ph.D., research assistant professor of medicine at the School of Medicine and one of the lead investigators of the study. "Instead, we realized this was a major finding."
Genetic analysis of healthy individuals confirmed the expected presence of two copies, or alleles, of the gene for osteoprotegerin. However, analysis of the JPD patients healthy parents revealed that each had only one copy of the gene. Furthermore, no osteoprotegerin was found in the blood of the two patients with JPD. The researchers conclude that these results provide both a cause and a mechanism for this rare bone disease, at least for these two Native Americans.
Thanks to simultaneous advances in the Human Genome Project, centered in part at Washington University, the team was able to pinpoint exactly where DNA had broken off in these two patients.
Again, the results were startling: The genetic damage was identical in both patients. The researchers therefore conclude that these two patients likely share a common ancestor, perhaps dating back a century.
"In a way, this also is a sociology story," says Whyte. "Our findings appear to represent the emergence of a "founder effect" in this population that underwent a "bottleneck" constriction years ago. The Navajo Nation decreased from about several hundred thousand individuals to about 6 thousand in the 1860s. As the population then re-grew, the missing gene apparently was passed on to their offspring. Eventually, people with only one copy of the osteoprotegerin gene married and had children with no copies of the gene."
The team now is evaluating other patients worldwide with varying forms of JPD, who so far do not appear to have any defects in the osteoprotegerin gene.
According to Whyte, this research will not only enable prenatal diagnosis for JPD in the Navajo population, but also suggests that osteoprotegerin may be a potential treatment for these affected individuals. They also expect their findings to help elucidate the role of osteoprotegerin and other key proteins in bone formation and breakdown, shedding light on Pagets disease of bone, osteoporosis and other common metabolic bone disorders.
Gila Z. Reckess | EurekAlert
Diabetes mellitus: A risk factor for early colorectal cancer
27.05.2020 | Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg
Ultra-thin fibres designed to protect nerves after brain surgery
27.05.2020 | Martin-Luther-Universität Halle-Wittenberg
In living cells, enzymes drive biochemical metabolic processes enabling reactions to take place efficiently. It is this very ability which allows them to be used as catalysts in biotechnology, for example to create chemical products such as pharmaceutics. Researchers now identified an enzyme that, when illuminated with blue light, becomes catalytically active and initiates a reaction that was previously unknown in enzymatics. The study was published in "Nature Communications".
Enzymes: they are the central drivers for biochemical metabolic processes in every living cell, enabling reactions to take place efficiently. It is this very...
Early detection of tumors is extremely important in treating cancer. A new technique developed by researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from normal tissue. The work is published May 25 in the journal Nature Nanotechnology.
researchers at the University of California, Davis offers a significant advance in using magnetic resonance imaging to pick out even very small tumors from...
Microelectronics as a key technology enables numerous innovations in the field of intelligent medical technology. The Fraunhofer Institute for Biomedical Engineering IBMT coordinates the BMBF cooperative project "I-call" realizing the first electronic system for ultrasound-based, safe and interference-resistant data transmission between implants in the human body.
When microelectronic systems are used for medical applications, they have to meet high requirements in terms of biocompatibility, reliability, energy...
Thomas Heine, Professor of Theoretical Chemistry at TU Dresden, together with his team, first predicted a topological 2D polymer in 2019. Only one year later, an international team led by Italian researchers was able to synthesize these materials and experimentally prove their topological properties. For the renowned journal Nature Materials, this was the occasion to invite Thomas Heine to a News and Views article, which was published this week. Under the title "Making 2D Topological Polymers a reality" Prof. Heine describes how his theory became a reality.
Ultrathin materials are extremely interesting as building blocks for next generation nano electronic devices, as it is much easier to make circuits and other...
Scientists took a leukocyte as the blueprint and developed a microrobot that has the size, shape and moving capabilities of a white blood cell. Simulating a blood vessel in a laboratory setting, they succeeded in magnetically navigating the ball-shaped microroller through this dynamic and dense environment. The drug-delivery vehicle withstood the simulated blood flow, pushing the developments in targeted drug delivery a step further: inside the body, there is no better access route to all tissues and organs than the circulatory system. A robot that could actually travel through this finely woven web would revolutionize the minimally-invasive treatment of illnesses.
A team of scientists from the Max Planck Institute for Intelligent Systems (MPI-IS) in Stuttgart invented a tiny microrobot that resembles a white blood cell...
19.05.2020 | Event News
07.04.2020 | Event News
06.04.2020 | Event News
29.05.2020 | Materials Sciences
29.05.2020 | Materials Sciences
29.05.2020 | Power and Electrical Engineering